Business
Clene Appoints Neurology Expert to Executive Team
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene
About this update from Clene Inc.
[{"type":"text","content":"SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical. An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). “Dr. Greenberg’s depth of experience will be invaluable to us as we advance the Phase 3 clinical development programs for CNM-Au8 in ALS and MS, especially as Ben has already been advising Clene for many years and is extremely familiar with CNM-Au8 and its data,” said, Rob Etherington, Clene’s CEO. “We are committed to help make neurodegenerative diseases treatable and believe that his contributions across our therapeutic areas of focus will be important. Robert Glanzman, MD FAAN, Clene’s current Chief Medical Officer will continue to serve the Company in an advisory role. We thank Dr. Glanzman for his work in advancing our lead asset to late-stage clinical development. We are well-positioned to continue disclosing additional data from our programs and will work to progress our discussions with potential pharma partners and regulatory agencies.” Dr. Greenberg joins Clene alongside his current role as professor of neurology and Vice Chair of Clinical and Translational Research in the Department of Neurology at UT Southwestern Medical Center in Dallas, TX. His clinical and research expertise spans many areas of neurology including the diagnosis and treatment of MS and other rare neurological disorders. Dr. Greenberg received his Bachelor’s degree from Johns Hopkins University and his Master’s degree in Molecular Microbiology and Immunology from the Johns Hopkins School of Public Health. He graduated from Baylor College of Medicine and completed an internal medicine internship at Rush Presbyterian-St. Luke’s Medical Center in Chicago, before going on to residency in neurology at The Johns Hopkins Hospital in Baltimore. “I am excited to join the incredible team ...